Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Entonil Crema is a topically applied medical device developed by Epitech Group SpA, specifically formulated to soothe skin reactions caused by insect bites, jellyfish, and nettles. The product is an ALIAmide-based cream containing adelmidrol, bromelain, and clove essential oil. It works through the ALIA (Autacoid Local Injury Antagonism) mechanism, where adelmidrol modulates the activity of cutaneous mast cells and non-neuronal immune cells to reduce allergic-inflammatory skin responses. Bromelain, a proteolytic enzyme, is included to assist in the elimination of irritating substances. Classified as a Class C Medical Device under EU Regulation 2017/745, Entonil Crema is marketed primarily for pediatric populations and is commercially available in Italian pharmacies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Entonil Crema.